MeSH term
Frequency | Condition_Probility | Adult | 16 | 0.0 |
Alleles | 4 | 0.0 |
Comparative Study | 3 | 0.0 |
DNA Mutational Analysis | 9 | 0.0 |
Electron Transport Complex II | 12 | 46.0 |
Female | 14 | 0.0 |
*Germ-Line Mutation | 9 | 2.0 |
Humans | 42 | 0.0 |
Male | 16 | 0.0 |
Middle Aged | 13 | 0.0 |
Multienzyme Complexes/*genetics | 6 | 8.0 |
Oxidoreductases/*genetics | 6 | 6.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Succinate Dehydrogenase/*genetics | 17 | 68.0 |
Age of Onset | 5 | 0.0 |
Aged | 8 | 0.0 |
Base Sequence | 5 | 0.0 |
Child | 5 | 0.0 |
Germ-Line Mutation | 6 | 1.0 |
*Mutation | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 20 | 0.0 |
Adolescent | 6 | 0.0 |
*Drosophila Proteins | 3 | 0.0 |
Heterozygote | 4 | 0.0 |
Hippel-Lindau Disease/genetics | 3 | 7.0 |
Iron-Sulfur Proteins/*genetics | 2 | 22.0 |
Multiple Endocrine Neoplasia Type 2a/genetics | 3 | 10.0 |
Mutation, Missense | 3 | 0.0 |
Pheochromocytoma/*genetics | 10 | 24.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Genetic Screening | 2 | 0.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Haplotypes | 3 | 0.0 |
Head and Neck Neoplasms/*genetics | 3 | 4.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Paraganglioma/*genetics | 9 | 60.0 |
Pedigree | 8 | 0.0 |
United States | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Electron Transport | 2 | 3.0 |
Genomic Imprinting | 2 | 1.0 |
Mutation | 6 | 0.0 |
Phenotype | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Adrenal Gland Neoplasms/genetics | 3 | 10.0 |
Head and Neck Neoplasms/genetics | 2 | 25.0 |
Membrane Proteins/*genetics | 5 | 0.0 |
Protein Subunits/*genetics | 5 | 26.0 |
Syndrome | 2 | 0.0 |
Thyroid Neoplasms/genetics | 2 | 7.0 |
Adrenal Gland Neoplasms/*genetics | 7 | 23.0 |
Chromosomes, Human, Pair 1/genetics | 3 | 1.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Loss of Heterozygosity | 6 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Neurofibromatosis 1/genetics | 2 | 6.0 |
Paraganglioma/genetics | 3 | 50.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics | 3 | 2.0 |
Genetic Markers | 2 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Penetrance | 2 | 1.0 |
Iron-Sulfur Proteins/genetics | 2 | 33.0 |
Succinate Dehydrogenase/genetics | 5 | 62.0 |
Electron Transport/genetics | 3 | 42.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Animals | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Introns/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Multienzyme Complexes/genetics | 3 | 12.0 |
Oxidoreductases/genetics | 3 | 8.0 |
*Mutation, Missense | 2 | 0.0 |
